Skip to main content
SpringerLink
Log in

Indications for Locoregional Tumor Therapies: CRC Liver Metastases

  • Chapter
  • First Online:
Locoregional Tumor Therapy

  • 332 Accesses

Abstract

The liver represents the most affected site in patients affected by colorectal carcinoma (mCRC) [1]. More than half cases develop colorectal liver metastases (CLMs) during the evolution of the disease, and about one-quarter occur at the disease onset [1, 2]. To date, the standard treatment of CLM is represented by liver surgery, which has allowed to achieve interesting long-term survival rates (40–60%) [3] in reported series, while it is less than 25% for patients who do not undergo surgery [4]. Unfortunately, most patients (80%), however, are not immediately eligible for surgery [5, 6]. For these patients, surgical treatment may be administered in combination with chemotherapy regimens (+/− target agents) aiming to downsize neoplasm and to allow a surgically and oncologically radical intervention. In addition, the greater effectiveness of the abovementioned new chemotherapeutic options has allowed to revolutionize the liver resection criteria considered until recently, thus widening the proportion of patients able to obtain long-term benefit from surgery. Locoregional liver treatments (including ablative technologies and transarterial treatments) can be considered additional options able to downsize CLMs and have been shown to improve quality of life, prolonging time to local progression and overall survival [7, 8]. Of course, to achieve optimal results, it is necessary to set up a multidisciplinary team, including interventionist radiologists, able to evaluate individual cases in order to select the best therapeutic strategy for each patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 56.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Garden OJ, Rees M, Poston GJ, et al. Guidelines for resection of colorectal cancer liver metastases. Gut. 2006;55(Suppl 3):iii1–8. https://doi.org/10.1136/gut.2006.098053.

    PubMed  PubMed Central  Google Scholar 

  2. Bengtsson G, Carlsson G, Hafström L, et al. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg. 1981;141(5):586–9.

    Article  CAS  PubMed  Google Scholar 

  3. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77(11):1241–6.

    Article  CAS  PubMed  Google Scholar 

  4. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759–66.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Poston GJ, Figueras J, Giuliante F, et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol. 2008;26(29):4828–33. https://doi.org/10.1200/JCO.2008.17.6453.

    Article  PubMed  Google Scholar 

  6. van den Eynde M, Hendlisz A. Treatment of colorectal liver metastases: a review. Rev Recent Clin Trials. 2009;4(1):56–62.

    Article  PubMed  Google Scholar 

  7. Ksienski D, Woods R, Speers C, et al. Patterns of referral and resection among patients with liver-only metastatic colorectal cancer (MCRC). Ann Surg Oncol. 2010;17(12):3085–93. https://doi.org/10.1245/s10434-010-1304-9.

    Article  PubMed  Google Scholar 

  8. Chiappa A, Makuuchi M, Lygidakis NJ, et al. The management of colorectal liver metastases: expanding the role of hepatic resection in the age of multimodal therapy. Crit Rev Oncol Hematol. 2009;72(1):65–75. https://doi.org/10.1016/j.critrevonc.2008.11.003.

    Article  CAS  PubMed  Google Scholar 

  9. Gillams A, Goldberg N, Ahmed M, et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts. The Interventional Oncology Sans Frontières Meeting 2013. Eur Radiol. 2015;25(12):3438–54. https://doi.org/10.1007/s00330-015-3779-z.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Nielsen K, van Tilborg AAJM, Meijerink MR, et al. Incidence and treatment of local site recurrences following RFA of colorectal liver metastases. World J Surg. 2013;37(6):1340–7. https://doi.org/10.1007/s00268-013-1997-6.

    Article  PubMed  Google Scholar 

  11. Hammill CW, Billingsley KG, Cassera MA, et al. Outcome after laparoscopic radiofrequency ablation of technically resectable colorectal liver metastases. Ann Surg Oncol. 2011;18(7):1947–54. https://doi.org/10.1245/s10434-010-1535-9.

    Article  PubMed  Google Scholar 

  12. Marchal F, Elias D, Rauch P, et al. Biliary lesions during radiofrequency ablation in liver. Study on the pig. Eur Surg Res. 2004;36(2):88–94. https://doi.org/10.1159/000076648.

    Article  CAS  PubMed  Google Scholar 

  13. Kingham TP, Karkar AM, D’Angelica MI, et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg. 2012;215(3):379–87. https://doi.org/10.1016/j.jamcollsurg.2012.04.029.

    Article  PubMed  Google Scholar 

  14. Gillams AR, Lees WR. Five-year survival following radiofrequency ablation of small, solitary, hepatic colorectal metastases. J Vasc Interv Radiol. 2008;19(5):712–7. https://doi.org/10.1016/j.jvir.2008.01.016.

    Article  PubMed  Google Scholar 

  15. Ruers T, Punt C, van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23(10):2619–26. https://doi.org/10.1093/annonc/mds053.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gillams AR, Lees WR. Radiofrequency ablation of colorectal liver metastases. Abdom Imaging. 2005;30(4):419–26. https://doi.org/10.1007/s00261-004-0256-6.

    Article  CAS  PubMed  Google Scholar 

  17. Reuter NP, Woodall CE, Scoggins CR, et al. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? J Gastrointest Surg. 2009;13(3):486–91. https://doi.org/10.1007/s11605-008-0727-0.

    Article  PubMed  Google Scholar 

  18. Tanaka K, Adam R, Shimada H, et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg. 2003;90(8):963–9. https://doi.org/10.1002/bjs.4160.

    Article  CAS  PubMed  Google Scholar 

  19. Adam R, Vibert E, Pitombo M. Chimiothérapie d’induction et chirurgie des métastases hépatiques du cancer colorectal (induction chemotherapy and surgery of colorectal liver metastases). Bull Cancer. 2006;93(Suppl 1):S45–9.

    CAS  PubMed  Google Scholar 

  20. Knudsen AR, Kannerup A-S, Mortensen FV, et al. Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy. Acta Radiol. 2009;50(7):716–21. https://doi.org/10.1080/02841850902991634.

    Article  PubMed  Google Scholar 

  21. Mitry E, Fields ALA, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008;26(30):4906–11. https://doi.org/10.1200/JCO.2008.17.3781.

    Article  CAS  PubMed  Google Scholar 

  22. Yamakado K, Inaba Y, Sato Y, et al. Radiofrequency ablation combined with hepatic arterial chemoembolization using degradable starch microsphere mixed with Mitomycin C for the treatment of liver metastasis from colorectal cancer: a prospective multicenter study. Cardiovasc Intervent Radiol. 2017;40(4):560–7. https://doi.org/10.1007/s00270-016-1547-3.

    Article  Google Scholar 

  23. Sartori S, Tombesi P, Di Vece F. Thermal ablation in colorectal liver metastases: lack of evidence or lack of capability to prove the evidence? World J Gastroenterol. 2016;22(13):3511–5. https://doi.org/10.3748/wjg.v22.i13.3511.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Ruers T, Punt CJA, van Coevorden F, et al. O-018 * Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): long-term survival results of a randomised phase II study of the EORTC-NCRI CCSG-ALM intergroup 40004 (CLOCC). Ann Oncol. 2015;26(suppl 4):iv114–5. https://doi.org/10.1093/annonc/mdv235.17.

    Article  Google Scholar 

  25. Solbiati L, Ahmed M, Cova L, et al. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology. 2012;265(3):958–68. https://doi.org/10.1148/radiol.12111851.

    Article  PubMed  Google Scholar 

  26. Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics. 2005;25(Suppl 1):S69–83. https://doi.org/10.1148/rg.25si055501.

    Article  PubMed  Google Scholar 

  27. Babawale SN, Jensen TM, Frøkjær JB. Long-term survival following radiofrequency ablation of colorectal liver metastases: a retrospective study. World J Gastrointest Surg. 2015;7(3):33–8. https://doi.org/10.4240/wjgs.v7.i3.33.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Stintzing S, Grothe A, Hendrich S, et al. Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases. Acta Oncol. 2013;52(5):971–7. https://doi.org/10.3109/0284186X.2013.766362.

    Article  PubMed  Google Scholar 

  29. Leung U, Kuk D, D’Angelica MI, et al. Long-term outcomes following microwave ablation for liver malignancies. Br J Surg. 2015;102(1):85–91. https://doi.org/10.1002/bjs.9649.

    Article  CAS  PubMed  Google Scholar 

  30. Shibata T, Niinobu T, Ogata N, et al. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer. 2000;89(2):276–84.

    Article  CAS  PubMed  Google Scholar 

  31. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Wallace S, Carrasco CH, Charnsangavej C, et al. Hepatic artery infusion and chemoembolization in the management of liver metastases. Cardiovasc Intervent Radiol. 1990;13(3):153–60.

    Article  CAS  PubMed  Google Scholar 

  33. Riemsma RP, Bala MM, Wolff R, et al. Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases. Cochrane Database Syst Rev. 2013;4:CD009498. https://doi.org/10.1002/14651858.CD009498.pub3.

    Google Scholar 

  34. Richardson AJ, Laurence JM, Lam VWT. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. J Vasc Interv Radiol. 2013;24(8):1209–17. https://doi.org/10.1016/j.jvir.2013.05.055.

    Article  PubMed  Google Scholar 

  35. Pellerin O, Geschwind J-F. Traitement intra-artériel des métastases hépatiques de cancer colorectal (Intra-arterial treatment of liver metastases from colorectal carcinoma). J Radiol. 2011;92(9):835–41. https://doi.org/10.1016/j.jradio.2011.07.008.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Liu DM, Thakor AS, Baerlocher M, et al. A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof. Future Oncol. 2015;11(9):1421–8. https://doi.org/10.2217/fon.15.3.

    Article  CAS  PubMed  Google Scholar 

  37. Clark TWI. Chemoembolization for colorectal liver metastases after FOLFOX failure. J Vasc Interv Radiol. 2013;24(1):66–7. https://doi.org/10.1016/j.jvir.2012.10.014.

    Article  PubMed  Google Scholar 

  38. Ceelen W, Praet M, Villeirs G, et al. Initial experience with the use of preoperative transarterial chemoembolization in the treatment of liver metastasis. Acta Chir Belg. 1996;96(1):37–40.

    CAS  PubMed  Google Scholar 

  39. Vogl TJ, Jost A, Nour-Eldin NA, et al. Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma. Br J Cancer. 2012;106(7):1274–9. https://doi.org/10.1038/bjc.2012.69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Vogl TJ, Gruber T, Balzer JO, et al. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology. 2009;250(1):281–9. https://doi.org/10.1148/radiol.2501080295.

    Article  PubMed  Google Scholar 

  41. Fiorentini G, Aliberti C, Turrisi G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo. 2007;21(6):1085–91.

    CAS  PubMed  Google Scholar 

  42. Martin RCG, Joshi J, Robbins K, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol. 2011;18(1):192–8. https://doi.org/10.1245/s10434-010-1288-5.

    Article  PubMed  Google Scholar 

  43. Aliberti C, Benea G, Tilli M, et al. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol. 2008;31(5):883–8. https://doi.org/10.1007/s00270-008-9336-2.

    Article  PubMed  Google Scholar 

  44. Martin RCG, Scoggins CR, Tomalty D, et al. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. J Gastrointest Surg. 2012;16(8):1531–8. https://doi.org/10.1007/s11605-012-1892-8.

    Article  PubMed  Google Scholar 

  45. Jones RP, Dunne D, Sutton P, et al. Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction: a case-control series. HPB (Oxford). 2013;15(1):71–7. https://doi.org/10.1111/j.1477-2574.2012.00587.x.

    Article  Google Scholar 

  46. Akinwande O, Miller A, Hayes D, et al. Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer. Anticancer Res. 2014;34(12):7239–45.

    CAS  PubMed  Google Scholar 

  47. Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32(4):1387–95.

    CAS  PubMed  Google Scholar 

  48. Martin RCG, Scoggins CR, Schreeder M, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121(20):3649–58. https://doi.org/10.1002/cncr.29534.

    Article  CAS  PubMed  Google Scholar 

  49. Khodjibekova M, Szyszko T, Khan S, et al. Selective internal radiation therapy with Yttrium-90 for unresectable liver tumours. Rev Recent Clin Trials. 2007;2(3):212–6.

    Article  CAS  PubMed  Google Scholar 

  50. Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65(2):412–25. https://doi.org/10.1016/j.ijrobp.2005.12.051.

    Article  CAS  PubMed  Google Scholar 

  51. Kennedy A. Radioembolization of hepatic tumors. J Gastrointest Oncol. 2014;5(3):178–89. https://doi.org/10.3978/j.issn.2078-6891.2014.037.

    PubMed  PubMed Central  Google Scholar 

  52. Atassi B, Bangash AK, Lewandowski RJ, et al. Biliary sequelae following radioembolization with Yttrium-90 microspheres. J Vasc Interv Radiol. 2008;19(5):691–7. https://doi.org/10.1016/j.jvir.2008.01.003.

    Article  PubMed  Google Scholar 

  53. Sag AA, Savin MA, Lal NR, et al. Yttrium-90 radioembolization of malignant tumors of the liver: gallbladder effects. Am J Roentgenol. 2014;202(5):1130–5. https://doi.org/10.2214/AJR.13.10548.

    Article  Google Scholar 

  54. Gray B, van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12(12):1711–20.

    Article  CAS  PubMed  Google Scholar 

  55. van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus Bevacizumab) versus mFOLFOX6 (plus or minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1723–31. https://doi.org/10.1200/JCO.2015.66.1181.

    Article  PubMed  Google Scholar 

  56. Townsend AR, Chong LC, Karapetis C, et al. Selective internal radiation therapy for liver metastases from colorectal cancer. Cancer Treat Rev. 2016;50:148–54. https://doi.org/10.1016/j.ctrv.2016.09.007.

    Article  PubMed  Google Scholar 

  57. Lewandowski RJ, Memon K, Mulcahy MF, et al. Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41(10):1861–9. https://doi.org/10.1007/s00259-014-2799-2.

    Article  CAS  PubMed  Google Scholar 

  58. Chan DL, Alzahrani NA, Morris DL, et al. Systematic review and meta-analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases. Surg Oncol. 2015;24(3):162–71. https://doi.org/10.1016/j.suronc.2015.06.014.

    Article  PubMed  Google Scholar 

  59. Allard M-A, Malka D. Place of hepatic intra-arterial chemotherapy in the treatment of colorectal liver metastases. J Visc Surg. 2014;151(Suppl 1):S21–4. https://doi.org/10.1016/j.jviscsurg.2013.12.003.

    Article  PubMed  Google Scholar 

  60. Kemeny N, Fata F. Arterial, portal, or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma. J Hepatobiliary Pancreat Surg. 1999;6(1):39–49.

    Article  CAS  PubMed  Google Scholar 

  61. Lévi FA, Boige V, Hebbar M, et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol. 2016;27(2):267–74. https://doi.org/10.1093/annonc/mdv548.

    Article  PubMed  Google Scholar 

  62. Malka D, Paris E, Caramella C, et al. Hepatic arterial infusion (HAI) of oxaliplatin plus intravenous (iv) fluorouracil (FU), leucovorin (LV), and cetuximab for first-line treatment of unresectable colorectal liver metastases (CRLM) (CHOICE): a multicenter phase II study. J Clin Oncol. 2010;28(15_suppl):3558. https://doi.org/10.1200/jco.2010.28.15_suppl.3558.

    Article  Google Scholar 

  63. Boige V, Malka D, Elias D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol. 2008;15(1):219–26. https://doi.org/10.1245/s10434-007-9581-7.

    Article  PubMed  Google Scholar 

  64. Kemeny NE, Melendez FDH, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27(21):3465–71. https://doi.org/10.1200/JCO.2008.20.1301.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Allard MA, Sebagh M, Baillie G, et al. Comparison of complete pathologic response and hepatic injuries between hepatic arterial infusion and systemic administration of oxaliplatin in patients with colorectal liver metastases. Ann Surg Oncol. 2015;22(6):1925–32. https://doi.org/10.1245/s10434-014-4272-7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Department, Antwerp University Hospital and Center for Oncological Research (CORE), Antwerp University, UZA, Edegem, Belgium

    Marc Peeters, Konstantinos Papadimitriou & Marika Rasschaert

  2. Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy

    Antonio Galvano & Antonio Russo

  3. Phase I-Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital and Center for Oncological Research (CORE), Antwerp University, UZA, Edegem, Belgium

    Christian Rolfo, David Arias Ron & Marika Rasschaert

Authors
  1. Marc Peeters
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio Galvano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christian Rolfo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Konstantinos Papadimitriou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Arias Ron
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marika Rasschaert
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Antonio Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc Peeters .

Editor information

Editors and Affiliations

  1. University Hospitals, Gasthuisberg and KU Leuven, Leuven, Belgium

    Eric Van Cutsem

  2. Department of Diagnostic Radiology, Johann Wolfgang Goethe University, Frankfurt, Germany

    Thomas J. Vogl

  3. Department of Interventional Radiology, European Institute of Oncology, Milano, Italy

    Franco Orsi

  4. IRCCS Ospedale San Martino IST, Genova, Italy

    Alberto Sobrero

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Peeters, M. et al. (2018). Indications for Locoregional Tumor Therapies: CRC Liver Metastases. In: Van Cutsem, E., Vogl, T., Orsi, F., Sobrero, A. (eds) Locoregional Tumor Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-69947-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-69947-9_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-69946-2

  • Online ISBN: 978-3-319-69947-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation